Almirall stock gains 1.84 percent to EUR 10.54 versus EUR 10.35

Published on 09/30/2026 at 10:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Almirall stock trades at EUR 10.54, up 1.84 percent versus the EUR 10.35 prior close on September 30, 2026. H1 2026 EBITDA rose 23.70 percent to EUR 150.70 million.

Dermatologe untersucht Patientenrücken mit Dermatoskop vor Barcelona-Skyline — Almirall S.A. (ES0157097017) zeigt Dermatologie-Praxis mit Hautuntersuchung und unbeschrifteten Cremetuben in Barcelona, Illustration mit AI erstellt.

Almirall stock (ISIN ES0157097017) was trading at EUR 10.54 at Lang & Schwarz on September 30, 2026 at 10:13 a.m. CEST, plus 1.84 percent versus the EUR 10.35 prior close. The medical dermatology company is using the EADV 2026 congress to present new clinical evidence across its portfolio.

Clinical evidence takes center stage

According to Business Wire on September 30, 2026, Almirall will present more than 20 abstracts at the European Academy of Dermatology and Venereology congress from September 30 to October 3, 2026.

The program covers atopic dermatitis, psoriasis and actinic keratosis. It includes new data for lebrikizumab and tildrakizumab, while a late-breaking study examines sustained results with up to five years of lebrikizumab treatment.

EBITDA grows faster than sales

In its H1 2026 results dated July 24, 2026, Almirall reported net sales of EUR 602.70 million, up 7.50 percent from H1 2025. EBITDA rose 23.70 percent to EUR 150.70 million, lifting the EBITDA margin to 25.00 percent from 21.70 percent.

The comparison points to stronger operating leverage: EBITDA growth exceeded sales growth by 16.20 percentage points. European dermatology sales increased 18.10 percent to EUR 341.90 million, giving the core franchise a faster growth rate than the group total.

Product performance also supplied measurable support. Ilumetri sales rose 10.50 percent to EUR 125.20 million, while Ebglyss sales increased 88.20 percent to EUR 84.50 million in the first half.

Guidance and next reporting date

Almirall reiterated 2026 guidance for net sales growth of 9.00-12.00 percent and EBITDA of EUR 270.00-290.00 million. The guidance range gives investors a defined benchmark for judging whether second-half execution can sustain the first-half margin improvement.

The investor calendar on Almirall lists the first nine months 2026 financial results for November 9, 2026. That date is the next scheduled reporting checkpoint for the sales and EBITDA trajectory.

Almirall stock gains in trading

Almirall stock was trading at EUR 10.54 at Lang & Schwarz on September 30, 2026 at 10:13 a.m. CEST, plus 1.84 percent versus the EUR 10.35 prior close. The 52-week range is EUR 10.02 to EUR 13.98, while market capitalization is EUR 2.3 billion as of September 30, 2026.